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Abstract: Background The optimal sequence of stereotactic radiotherapy (SRT) and immune checkpoint
inhibition (ICI) and assessment of response in patients with brain metastases from melanoma remain chal-
lenging. Methods We reviewed clinical and neuroimaging data of 62 patients with melanoma, including
26 patients with BRAF-mutant tumours, with newly diagnosed brain metastases treated with ICI alone
(n=10, group 1), SRT alone or in combination with other systemic therapies (n=20, group 2) or ICI plus
SRT (n=32, group 3). Response was assessed retrospectively using response evaluation criteria in solid
tumours (RECIST) V.1.1, response assessment in neuro-oncology (RANO) and immunotherapy RANO
(iRANO) criteria. MRI follow-up from 43 patients was available for central review. Results Patients
treated with ICI alone showed no objective responses and had worse outcome than patients treated with
SRT without or with ICI. RECIST, RANO and iRANO criteria were concordant for complete response
(CR) and partial response (PR). RANO called progression earlier than RECIST for clinical deterioration
without MRI progression in some patients. Progression was called later when using iRANO criteria be-
cause of the need for a confirmatory scan. Pseudoprogression was documented in seven patients: three
patients in group 2 and four patients in group 3. Radionecrosis was documented in seven patients: two
patients in group 2 and five patients in group 3. Regression of non-irradiated lesions was seen neither in
two patients treated with SRT alone nor in five patients treated with SRT plus ICI, providing no evidence
for rare abscopal effects. Conclusions Pseudoprogression is uncommon with ICI alone, suggesting that
growing lesions in such patients should trigger an intervention. Pseudoprogression rates were similar
after SRT alone or SRT in combination with ICI. Abscopal effects are rare or do not exist. Response
assessment criteria should be considered carefully when designing clinical studies for patients with brain
metastases who receive SRT.
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ABSTRACT
Background The optimal sequence of stereotactic 
radiotherapy (SRT) and immune checkpoint inhibition 
(ICI) and assessment of response in patients with brain 
metastases from melanoma remain challenging.
Methods We reviewed clinical and neuroimaging data 
of 62 patients with melanoma, including 26 patients 
with BRAF- mutant tumours, with newly diagnosed brain 
metastases treated with ICI alone (n=10, group 1), SRT 
alone or in combination with other systemic therapies 
(n=20, group 2) or ICI plus SRT (n=32, group 3). Response 
was assessed retrospectively using response evaluation 
criteria in solid tumours (RECIST) V.1.1, response 
assessment in neuro- oncology (RANO) and immunotherapy 
RANO (iRANO) criteria. MRI follow- up from 43 patients was 
available for central review.
Results Patients treated with ICI alone showed no 
objective responses and had worse outcome than patients 
treated with SRT without or with ICI. RECIST, RANO and 
iRANO criteria were concordant for complete response 
(CR) and partial response (PR). RANO called progression 
earlier than RECIST for clinical deterioration without MRI 
progression in some patients. Progression was called 
later when using iRANO criteria because of the need for a 
confirmatory scan. Pseudoprogression was documented in 
seven patients: three patients in group 2 and four patients 
in group 3. Radionecrosis was documented in seven 
patients: two patients in group 2 and five patients in group 
3. Regression of non- irradiated lesions was seen neither 
in two patients treated with SRT alone nor in five patients 
treated with SRT plus ICI, providing no evidence for rare 
abscopal effects.
Conclusions Pseudoprogression is uncommon with ICI 
alone, suggesting that growing lesions in such patients 
should trigger an intervention. Pseudoprogression rates 
were similar after SRT alone or SRT in combination with 
ICI. Abscopal effects are rare or do not exist. Response 
assessment criteria should be considered carefully 
when designing clinical studies for patients with brain 
metastases who receive SRT.
IntRoduCtIon
Patients with metastatic melanoma carry a 
high lifetime risk of developing brain metas-
tasis (BM). The outcome for these patients 
improved when whole brain radiotherapy 
was substituted by stereotactic radiotherapy 
(SRT)1 and when effective targeted thera-
pies for BRAF- mutant tumours2 3 as well as 
immune checkpoint inhibition (ICI) were 
introduced.4–6 However, both treatment 
modalities, SRT and ICI, have caused new 
challenges when evaluating neuroimaging by 
MRI which is considered the gold standard of 
monitoring response during follow- up. It is 
Key points
What is already known about this subject?
Metastases to the central nervous system are an 
increasing challenge in general oncology, specifical-
ly in melanoma. They may affect up to 30% of all 
patients with cancer and are a major source of mor-
bidity and mortality. As patients with cancer survive 
longer because of improved medical treatments, the 
control of brain metastasis (BM) emerges as a major 
goal of cancer treatment in general.
How might this impact on clinical practice?
 ► While the novel systemic therapies including immu-
notherapy and targeted treatment contribute to the 
control of BM, radiotherapy has traditionally been the 
mainstay of treatment of BM. One of the major cur-
rent controversies centres on the optimal timing of 
focal radiotherapy for BM: should it be administered 
upfront to optimise local control, with a potential risk 
of neurotoxicity in long- term surviving patients, or 
should radiotherapy be delayed until systemic thera-
py has failed? And how do we address the challeng-
es experienced with neuroimaging- based response 
assessment? Do abscopal effects truly exist in this 
patient population?
How might this impact on clinical practice?
 ► The present study illustrates several pitfalls in the 
assessment of these patients. It does not support 
that abscopal effects are common and, regarding 
outcome, lends support to the notion that stereotac-
tic radiotherapy should not be readily abandoned as 
a first- line treatment option.
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not surprising that a treatment like SRT that is designed 
to eradicate metastatic lesions causes tissue damage, 
but differentiating this tissue damage from progressive 
tumour growth has turned out to be difficult. Further-
more, ICI treatment is meant to induce an immune and 
associated inflammatory response to metastatic lesions, 
and these changes would also be expected to resemble 
progressive tumours. These considerations have led the 
response assessment in neuro- oncology (RANO) group 
to design specific response criteria for patients with brain 
tumours exposed to immunotherapy already in 2015 
when little data on specific challenges in the assessment 
of BM were available.7 Since then response assessment 
in BM treated with SRT or ICI remains to be an issue 
of controversy primarily in clinical practice, and in the 
conduct of clinical trials.
Compared with the response evaluation criteria in 
solid tumours (RECIST) criteria,8 RANO criteria for BM 
were expanded to also include clinical status and steroid 
medication within the response criteria9 (online supple-
mentary table S1). The major goal of the immunotherapy 
RANO (iRANO) criteria was to make sure that patients 
are not taken off a potentially effective treatment prema-
turely.7 immune (i)RECIST criteria have been introduced 
with a similar rationale.10 The present retrospective anal-
ysis compared how clinical decision making should have 
evolved when either of these sets of criteria was used and 
compared these data with the treatment that was actually 
administered in real life.
PatIents and Methods
Patients
We retrospectively reviewed the charts of consecutive 
patients with histologically confirmed melanoma that 
were newly diagnosed with BM, fulfilled criteria of meas-
urable disease by RANO,9 and were treated, without or 
with prior surgical resection, with ICI targeting cytotoxic 
T lymphocyte antigen (CTLA) 4, programmed death 
(PD)−1 or PD- ligand (PD- L) 1 (group 1), SRT without 
or with non- immuno- oncology (IO) pharmacotherapy 
(group 2), or ICI plus SRT (group 3). Patients were 
assigned to group 3 if the time interval between SRT and 
IO was less than 90 days. The parameters documented in 
the electronic case report form (eCRF) are summarised 
in online supplementary table S2.
study design
The main objective was to determine response based 
on the application of RECIST 1.1, RANO and iRANO 
criteria (online supplementary table S1). Furthermore, 
we assessed the frequency of pseudoprogression and 
radionecrosis on standard MRI sequences and explored 
the pattern of central nervous system (CNS) progres-
sion including any potential abscopal effect. Pseudopro-
gression was defined as an increase of lesion volume of 
25% or more that resolved without institution of a new 
anticancer treatment except steroids. Radionecrosis was 
defined as the appearance of necrosis within the treated 
target volume irrespective of size. We explored two oper-
ational definitions of abscopal effects induced by SRT: 
(A) An abscopal effect can be stated when there is a 
significant reduction of the volume of a distant lesion 
not treated by SRT in a SRT- treated patient who received 
no concomitant systemic treatment; (B) abscopal effects 
can be postulated if ICI induces a better outcome when 
combined with SRT compared with ICI alone, excluding 
irradiated lesions as target lesions.
Data on progression- free survival (PFS) as assessed by 
the treating physicians were compiled for 3- month inter-
vals from BM- directed treatment to progression at any 
site. CNS progression was defined as time from BM- di-
rected treatment to progression anywhere in the CNS. 
Target- specific PFS was determined for irradiated lesions 
in groups 2 and 3. These PFS parameters were based on 
imaging alone. Extra- CNS PFS was defined as the time 
from BM- directed treatment to extra- CNS progression. 
Global PFS was defined as the time from BM- directed 
treatment to first progression. In addition, we explored 
whether clinical neurological progression occurred 
in the absence of MRI progression on neuroimaging. 
Overall survival (OS) was defined as the time from BM- di-
rected treatment to death or last follow- up. Neuroim-
aging data of 43 patients were centrally reviewed. All data 
were extracted from medical records. The melanoma 
Diagnosis- specific Graded Prognostic Assessment Score 
(DS GPA) was determined as described.11
statistical analysis
Descriptive analyses were performed in order to check 
and summarise the data. Survival rates were determined 
using the Kaplan- Meier method. Survival curves were 
compared between groups using the log- rank test. Statis-
tical analyses were performed using SAS software V.9.4 
(Cary, North Carolina, USA).
Results
Patient characteristics
A total of 62 patients was studied (Lille, n=36, diagnosed 
November 2008 to May 2017; Zurich, n=26, diagnosed 
November 2010 to April 2017). The melanoma history 
is summarised in online supplementary table S3. The 
median Breslow Index at melanoma diagnosis was 3 
(interquartile range (IQR 1.5–5.5). A BRAF mutation was 
present in tumours of 26 patients (42%). At the time of 
melanoma diagnosis, distant metastases were identified in 
17 patients, including 9 patients with BM. Treatment prior 
to BM diagnosis included chemotherapy for 6 patients, 
targeted therapy for 8 patients and immunotherapy for 
18 patients. Ten patients were treated by ICI targeting 
CTLA-4, PD-1 or PD- L1 (group 1). Twenty patients were 
treated by SRT without or with non- ICI pharmacotherapy 
(group 2), and 32 patients were treated by ICI plus SRT 
(group 3). In the latter group, 25 patients received the 
combined treatment within 1 month, whereas the time 
Open access
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ICI plus stereotactic 
radiotherapy
(n=32)
Age at BM diagnosis (years): 
median (IQR)
58 (45–68) 58 (47–71) 55 (43–63) 58 (51–69)
KPS at BM diagnosis (n, %)
  90-100 35 (56) 6 (60) 13 (65) 16 (50)
  70-80 25 (40) 4 (40) 7 (35) 14 (44)
  <70 2 (3) 0 (0) 0 (0) 2 (6)
  Median KPS (IQR) 90 (80–100) 95 (80–100) 90 (80–100) 85 (80–92)
Time interval between 
diagnosis of melanoma and 
diagnosis of BM in months: 
median (IQR)
23 (9–43) 22 (15–25) 19 (13–40) 28 (7–50)
New metastatic sites outside 
CNS at BM diagnosis
30 (48) (3 n=59) 6 (60) (n=10) 9 (45) (1 n=9) 15 (47) (2 n=30)
Symptoms and signs (n, %)
  Seizures 9 (14) 0 2 (10) 7 (22)
  Paresis 15 (24) 0 3 (15) 12 (37)
  Aphasia 7 (11) 0 0 (0) 7 (22)
  Visual disturbance 4 (6) 0 0 (0) 4 (12)
  Sensory deficits 8 (13) 0 3 (15) 5 (16)
  Headache 14 (23) (n=31) 0 7 (35) 7 (22) (n=31)
  Psychiatric and cognitive 
disorders
8 (13) 0 2 (10) 6 (19)
  Cerebellar and brainstem 
symptoms
1 (2) (n=30) 0 1 (5) (n=9) 0 (0) (n=31)
  Other symptoms 1 (2) (n=31) 0 0 (0) (n=9) 1 (3)
  Asymptomatic 31 (50) 10 (100) 8 (40) 13 (41)
LDH level at BM diagnosis 
(n, %)
  Elevated 14 (23) 3 (30) 5 (25) 6 (19)
  Normal 36 (58) 6 (60) 8 (40) 22 (69)
  No data 12 (19) 1 (10) 7 (35) 4 (12)
  Median LDH level (IQR) 326 (251–449) (n=43) 262 (197–353) (n=7) 397 (284–492) (n=11) 321 (268–412) (n=25)
DS- GPA at BM diagnosis: 
median (IQR)
2 (1.5-.2.5) 1.75 (1.1–2.4) 2.5 (1.5–3) 2 (1.5–2.5)
Number of BM (n, %)
  1 34 (55) 4 (40) 14 (70) 16 (50)
  2 13 (21) 0 (0) 2 (10) 11 (34)
  3 6 (10) 1 (10) 3 (15) 2 (6)
  4 1 (2) 1 (10) 0 (0) 0 (0)
  5 2 (3) 1 (10) 0 (0) 1 (3)
  >5 6 (10) 3 (30) 1 (5) 2 (6)
  Median (IQR) 1 (1–2) 3.5 (1.5–5.75) 1 (1–2) 1.5 (1–2)
Maximum diameter of largest 
BM: median (IQR)
18 (13–25) 13 (10–15) 21 (17–24) 18 (14–25)
Continued
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ICI plus stereotactic 
radiotherapy
(n=32)
BM with a maximal diameter 
>30 mm (n, %)
9 (14) 0 5 (25) 4 (12))
Necrotic BM (n, %) 6 (10) (n=59) 0 (n=9) 3 (15) (n=19) 3 (9) (n=31)
Cystic BM (n, %) 8 (13) (n=61) 0 (n=9) 2 (10) (n=20) 6 (19) (n=32)
Haemorrhagic BM (n, %) 19 (31) (n=58) 1 (11) (n=9) 5 (25) (n=18) 13 (41) (n=31)
Significant oedema (n, %) 42 (68) (n=59) 5 (50) (n=10) 14 (70) (n=17) 23 (72) (n=32)
Oedema, mm: median (IQR) 10.5 (1.5–17) (n=54) 0 (0–5.5) (n=7) 18 (10–25) (n=17) 10 (2–14) (n=30)
The number of patients is given when not all the data are available.
*Two patients had multiple brain metastases and were considered with 10 metastases.
BM, brain metastases; CNS, central nervous system; DS- GPA, diagnosis- specific graded prognostic assessment; ICI, immune checkpoint 
inhibition; KPS, Karnofsky Performance Score; LDH, lactate dehydrogenase; n, number of patients.
Table 1 Continued
Figure 1 Outcomes by group assignments: (A) CNS-PFS. (B) Global PFS. (C) Extra- CNS. (D) OS. CNS, central nervous 
system; ICI, immune checkpoint inhibition; OS, overall survival; PFS, progression- freesurvival; SRT, stereotactic radiotherapy.
interval was greater than 30 days for 7 patients (SRT first 
for 3 patients with a time interval of 38, 46 and 83 days; 
ICI first for 4 patients with a time interval of 38, 42, 44, 
62 days).
Presentation of BM
Median age at BM diagnosis was 58 years (IQR 45–68), 
median Karnofsky Performance Score was 90 (IQR 
80–100). The median interval from diagnosis of the 
primary tumour to the diagnosis of BM was 23 months 
(IQR 9–43). The most frequent neurological symptoms 
and signs at BM diagnosis were headaches and paresis, 
but 31 patients (50%) were asymptomatic for BM. Thirty- 
four patients (55%) had one BM, 19 patients (31%) 
two to three BM, 3 patients (5%) four to five BM and 
six patients (10%) had more than five BM. The median 
maximum diameter of the largest BM was 18 mm (IQR 
13–25). BM were haemorrhagic in 19 patients (31%). 
Perilesional oedema of at least 20% of the BM diameter 
was noted in 42 patients (68%). A comparison of groups 
showed that group 1 patients had more often multiple, 
and more often smaller BM characteristics whereas BM in 
groups 2 and 3 were similar (table 1).
treatment characteristics and follow-up
In response to BM diagnosis, 14 patients (22%) were 
treated with antiepileptic drugs and 29 patients (47%) 



















Table 2 BM treatment characteristics and outcome[‡]
All patients Group 1 Group 2 Group 3
ICI alone
Stereotactic radiotherapy 
without or with non- ICI 
pharmacotherapy
ICI plus stereotactic 
radiotherapy
(n=62) (n=10) (n=20) (n=32)
Concomitant medication
Antiepileptic drugs (n, %)
  No antiepileptic drug 34 (55) 8 (80) 9 (45) 17 (53)
  Initiated at BM diagnosis 14 (22) 0 (0) 1 (5) 13 (41)
  During the course of BM diagnosis 14 (22) 2 (20) 10 (50) 2 (6)
Steroid intake at BM diagnosis (n, %) 29 (47)
(n=61)
1 (10) 12 (60) 16 (50)
(n=31)
Steroid dose (dexamethasone equivalent) at BM diagnosis (n, 
IQR)
13 (10–16) 10 (10–10) 10 (6–15) 16 (12–16)
(n=29) (n=1) (n=12) (n=16)







Any neurosurgical intervention (n, %) 22 (35) 0 (0) 7 (35) 15 (47)
Time interval between BM diagnosis by imaging and surgery in 
days: median (IQR)
8 (5–19) (n=22) n.a. 6 (4–7.5) (n=7) 8 (5–20) (n=15)
Type of surgery: (n, % among operated patients)
  Partial resection 7 (32) 0 (0) 2 (28) 4 (27)
  Gross total resection 15 (68) (n=22) 0 (0) (n=0) 5 (71) (n=7) 11 (73) (n=15)
Radiotherapy (RT)
RT for surgical cavity in operated patients (n, %) 19 (86) (n=22) n.a. 6 (86) (n=7) 13 (87) (n=15)
RT in addition to surgical bed/RT for further lesions (n, % among patients treated with SRS/SRT)
  SRS 27 (52) n.a. 13 (65) 14 (44)
  FSRT 24 (46) 7 (35) 17 (53)
  SRS and FSRT 1 (2) (n=52) 0 (0) (n=20) 1 (3) (n=32)
For SRS or FSRT, number of targets (n, % among patients treated with SRS/SRT)
  1 36 (69) n.a. 15 (75) 21 (66)
  2 9 (17) 2 (10) 7 (22)
  3 5 (10) 3 (15) 2 (6)





















All patients Group 1 Group 2 Group 3
ICI alone
Stereotactic radiotherapy 
without or with non- ICI 
pharmacotherapy
ICI plus stereotactic 
radiotherapy
(n=62) (n=10) (n=20) (n=32)
Number of targets: median (IQR) 1 (1–2) 1 (1–1.25) 1 (1–2)
  (n=52) (n=20) (n=32)






For SRS or FSRT, total volume treated in ml (median, IQR) 4 (2–9) n.a. 3 (2–8) 4 (3–9)
(n=48) (n=19) (n=29)
Time interval between BM diagnosis by imaging and first dose 
of RT in days (median, IQR)




  Any 42 (68) 10 (100) n.a. 32 (100)
  Ipilimumab 21 (34) 6 (60) 15 (47)
  Nivolumab 5 (8) 0 (0) 5 (16)
  Pembrolizumab 15 (24) 4 (40) 11 (34)
  Ipilimumab + nivolumab 1 (2) 0 (0) 1 (3)
Time interval between SRS or first dose of FSRT and first dose of ICI in days (median, IQR)
  RT prior to ICI n.a. n.a. 14 (9–25) (n=15)
  ICI prior to RT 18 (11–30) (n=16)*
Median duration of ICI in months: median (IQR) 2 (1–5) 2 (1–2) n.a. 2 (1–6)
ICI- related AE leading to permanent stop of IO treatment (n, % 
among patients treated with ICI)
10 (24) 1 (10) n.a. 9 (28)
Systemic targeted therapy
n (n (%) n.a. n.a.
  Any 5 (8) 5 (25)
  Vemurafenib 1 (2) 1 (5)
  Dabrafenib 1 (2) 1 (5)
  Vemurafenib + cobimetinib 2 (3) 2 (10)





















All patients Group 1 Group 2 Group 3
ICI alone
Stereotactic radiotherapy 
without or with non- ICI 
pharmacotherapy
ICI plus stereotactic 
radiotherapy
(n=62) (n=10) (n=20) (n=32)
Time interval between SRS or FSRT and systemic targeted 
therapy (TT) in days (median, range)
n.a. n.a.
  RT prior to TT 8 (8–8) (n=1) 8 (8–8) (n=1)
  TT prior to RT 17 (13–22) (n=4) 17 (13–22) (n=4)
Systemic chemotherapy
n (n (%) n.a.
  Any 7 (11) 2† (20) 5 (25)
  Fotemustine 1 (2) 1 (10) 1 (5)
  Temozolomide 5 (8) 0 (0) 4 (20)
  Cyclophosphamide 1 (2) 1 (10) 0 (0)
Time interval between SRS or FSRT and systemic 
chemotherapy in days (median, IQR)
n.a.
  RT prior to chemotherapy 14 (14–14) (n=1) n.a. 14 (14–14) (n=1)
  Chemotherapy prior to RT 18 (12–23) (n=4) 18 (12–23) (n=4)
Outcome
CNS progression (n, %) 37 (60) 9 (90) 14 (70) 17 (53)
CNS PFS from BM diagnosis in months (median, IQR) 5 (3–17) 3 (1–4) 7 (4–42) 6 (3–28)
CNS PFS from first BM treatment in months (median, IQR) 5 (3–16) 2 (2–3) 7 (4–42) 5 (3–26)
Type of CNS progression (n, type of CNS progression (n, %)
  Brain 29 (46) 9 (90) 9 (45) 11 (34)
  Leptomeningeal metastases 3 (5) 0 (0) 1 (5) 2 (6)
  Both 8 (13) 1 (10) 3 (15) 4 (12)
  None 19 (31) 0 (0) 6 (30) 13 (41)
  Unknown 3 (5) 0 (0) 1 (5) 2 (6)
Pattern of BM progression (n, %)
  Local 10 (16) 2 (20) 2 (10) 6 (19)
  Distant 21 (34) 3 (30) 9 (45) 9 (28)
  Both 7 (11) 4 (40) 1 (5) 2 (6)






















All patients Group 1 Group 2 Group 3
ICI alone
Stereotactic radiotherapy 
without or with non- ICI 
pharmacotherapy
ICI plus stereotactic 
radiotherapy
(n=62) (n=10) (n=20) (n=32)
  Unknown 5 (8) 1 (10) 2 (10) 2 (6)
Extra- CNS progression at the time of brain progression (n, %)
  Progression 29 (47) 3 (30) 11 (55) 15 (47)
  Stability 5 (8) 0 (0) 1 (5) 4 (12)
  Improvement 2 (3) 0 (0) 1 (5) 1 (3)
  None 16 (26) 2 (20) 4 (20) 10 (31)
  Unknown 10 (16) 5 (50) 3 (15) 2 (6)
Extra- CNS PFS from BM diagnosis in months (median, IQR) 5 (3–12) 3 (3–22) 6 (3–21) 5 (3–28)
Extra- CNS PFS from first BM treatment in months (median, 
IQR)
5 (3–11) 3 (2–20) 7 (4–22) 4 (3–14)
Any first progression (n,%)
  Yes 54 (87) 10 (100) 19 (95) 25 (78)
  No 7 (11) 0 1 (5) 6 (19)
  Death without precision 1 (2) 0 0 1 (3)
Global PFS from BM diagnosis in months (median, IQR) 5 (3–7) 3 (1–4) 6 (4–22) 5 (3–13)
Global PFS from first BM treatment in months (median, IQR) 4 (2–6) 2 (2–3) 6 (3–21) 3 (3–12)
Type of any first progression (n, %)
  LM 0 (0) 0 (0) 0 (0) 0 (0)
  BM 14 (22) 6 (60) 3 (15) 5 (16)
  Extra- CNS 17 (27) 0 (0) 8 (40) 9 (28)
  LM and BM 1 (2) 1 (10) 0 (0) 0 (0)
  LM and extra- CNS 1 (2) 0 (0) 0 (0) 1 (3)
  BM and extra- CNS 18 (29) 3 (30) 7 (35) 8 (5)
  LM and BM and extra- CNS 3 (5) 0 (0) 1 (5) 2 (6)
  None 1 (3) 0 (0) 0 (0) 1 (3)
  Unknown 7 (11) 0 (0) 1 (5) 6 (19)
Treatment after any progression
  Yes 40 (74) 5 (50) 16 (84) 19 (76)





















All patients Group 1 Group 2 Group 3
ICI alone
Stereotactic radiotherapy 
without or with non- ICI 
pharmacotherapy
ICI plus stereotactic 
radiotherapy
(n=62) (n=10) (n=20) (n=32)
  (n=54) (n=10) (n=19) (n=25)
Median time to next treatment after progression in days 
(median, IQR)
22 (7–46) 15 (8–17) 20 (6–46) 28 (8–46)
Death (n, %) 48 (77) 8 (80) 18 (90) 22 (69)
Cause of death (n, % among deceased patients)
  Neurological 21 (27) 5 (62) 8 (44) 8 (36)
  Extra- CNS 5 (10) 1 (12) 3 (17) 1 (4)
  Neurological and extra- CNS 3 (6) 0 (0) 0 (0) 3 (0)
  Complication of treatment 2 (4) 0 (0) 1 (6) 2 (9)
  Other 3 (6) 0 (0) 1 (6) 2 (9)
  Unknown 13 (27) 2 (24) 5 (28) 6 (27)
  (n=48) (n=8) (n=18) (n=22)
OS from BM diagnosis in months (median, IQR) 11 (6–27) 6 (3–23) 14 (10–42) 11 (7–28)
OS from first BM treatment in months (median, IQR) 11 (6–25) 5 (3–21) 13 (8–42) 11 (6–27)
*One patient had both treatment (SRT and ICI) on the same day.
†Two patients received a combination of ICI and chemotherapy.
‡Among the whole cohort, unless specified.
§The number of patients is given when not all the data are available. % among the whole cohort, unless specified 
AE, adverse event 
; BM, brain metastases; CNS, central nervous system; Gy, Grey; ICI, immune checkpoint inhibition; IO, immuno- oncology; LM, leptomeningeal metastases; n, number of patients; OS, overall 
survival; PFS, progression- free survival; SRS, stereotactic radiosurgery; SRT, stereotactic radiotherapy.
Table 2 Continued
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Figure 2 Response patterns. (A) Pseudoprogression: a 65- year- old man treated with SRT (6×5 Gy) to the surgical bed in 
April 2017, followed by four cycles of ipilimumab from April to July 2017. (B) Radionecrosis: A 57- year- old woman treated with 
SRT (5×5) February to March 2013, followed by four cycles of ipilimumab from February to April 2013. (C) CR: A 35- year- old 
woman treated with SRT (1×20 Gy) in February 2016, followed by three cycles of pembrolizumab. Gy, Grey; SRT, stereotactic 
radiotherapy.
surgery for BM was performed in 22 patients (35%), 
with a gross total resection in 15 (68%) of these patients. 
Seven of these 15 patients (47%) had two BM- suspi-
cious lesions and 2 patients had three BM- suspicious 
lesions that were all treated by SRT. The rates of surgery 
differed substantially: none in group 1, 7 patients (35%) 
in group 2 and 15 patients (47%) in group 3. SRT to the 
surgical bed was performed in 19 patients (86%). Group 
2 patients received SRT with a median number of 1 target 
(IQR 1–1.25), a median dose of 25 Gray (Gy) (24–25) 
and a median volume of 3 mL (2–8). Group 3 patients 
received SRT with a median number of targets of 1 (IQR 
1–2), a median dose of 27 Gy (IQR 25–30), and a median 
volume of 4 mL (IQR 3–9). In group 3, ICI was started 
prior to SRT in 15 patients and after SRT in 16 patients 
each. The median interval between start of SRT and start 
of ICI was 14 days (IQR 9–25) when SRT was initiated 
first. The median interval between start of ICI and start 
of SRT was 18 days (IQR 11–30) when ICI was initiated 
first. One patient had both treatments on the same day. 
Ten patients developed an adverse event severe enough 
to stop ICI treatment, one in group 1 (hypophysitis) and 
nine in group 3 (colitis, n=3; interstitial nephritis, n=1; 
interstitial pneumopathy, n=1; exanthema, hypophysitis, 
encephalitis pneumopathy, n=1; hepatitis and throm-
bosis, n=1; hepatitis, n=1; thyroiditis, n=1).
After a median follow- up of 30.5 months for surviving 
patients, 37 patients (60%) had experienced CNS progres-
sion, 9 patients (90%) in group 1, 14 (patients 70%) in 
group 2 and 17 patients (53%) in group 3. Median CNS- 
related PFS was lowest in group 1. CNS progression was 
BM in 29 (46%) patients: 9 patients (90%) in group 1, 9 
patients (45%) in group 2 and 11 patients (34%) in group 
3. Leptomeningeal metastasis (LM), alone or combined 
with BM progression, was observed in 11 patients (18%); 
1 patient (10%) in group 1, 4 patients (20%) in group 
2 and 6 patients (18%) in group 3. Among 22 patients 
operated for BM, 6 patients (27%) developed LM (1 LM 
only, 5 BM and LM). Among 40 patients not operated, 5 
patients (12.5%) developed LM (2 LM only, 2 BM and 
LM). Median survival of operated versus non- operated 
patients was 12 (IQR 7–28) vs 11 (IQR 4–22) months. 
Forty- eight patients (77%) had died at the time of the 
analysis; 8 patients (80%) in group 1, 18 patients (90%) 
in group 2 and 22 patients (69%) in group 3. CNS disease 
only or in combination with extra- CNS disease was a cause 
of death in 5 patients (50%) in group 1, in 5 patients 
(62%) in group 2 and in 11 patients (50%) in group C. 
Median OS was shortest in group 1 (figure 1, table 2).
Retrospective review of response: landmark analyses
Online supplementary table 4 summarises response 
status per local assessment and survival status at 3, 6, 9 
and 12 months. The data overall indicate poor control 
by ICI alone and similar outcome in patients treated 
with SRT with or without ICI. Complete MRI sequences 
during follow- up for post hoc review were available for 
43 patients. Patients who did not undergo MRI, but who 
deteriorated clinically were not taken into account for 
this analysis since no RECIST or imaging only assessment 
could be performed on these patients. Representative 
patients illustrating some of the challenges are shown 
in figure 2. Assessment of local response of SRT targets 
in groups 2 and 3 revealed very few complete responses 
(CRs) and comparable overall response rates that did not 
differ using RECIST or RANO criteria. Fewer progressive 
disease (PD) were observed when using iRANO criteria 
in both groups since iRANO requires a confirmatory scan 
in patients with apparently worse MRI who are clinically 
stable (table 3). Similar results were obtained when using 
RECIST or RANO regarding the overall brain response. 
Less PD were also noted when using iRANO criteria.
Retrospective evaluation of best response
For SRT targets, CR was the best response in six patients 
and partial response (PR) was the best response in eight 
Open access
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Table 3 Radiological response assessment by central review (for patients without treatment changes and with available MRI 
scans): response at 3 months and 6 months for SRT targets and overall brain
All patients
Group 1 Group 2 Group 3
ICI alone
SRT without or with non- 
ICI pharmacotherapy ICI plus SRT
MRI response for SRT targets 
in groups 2 and 3 at 3 months
(n=36)* n.a. (n=11)* (n=25)*
Local assessment (n, %) (n=
  PD 6 (15) n.a. 2 (13) 4 (16)
  SD 15 (37) 6 (40) 9 (36)
  PR/CR 15 (37) 6 (40) 9 (36)
  data incomplete 4 (10) 1 (7) 3 (12)
  (n=40)† (n=15)† (n=25)†
RECIST V.1.1 (MRI only) (n, %) 
(n=40)
  PD 7 (19) n.a. 3 (27) 4 (16)
  SD 8 (22) 2 (18) 6 (24)
  PR 10 (27) 4 (36) 6 (24)
  CR 2 (5) 0 2 (8)
  Data incomplete 9 (25) 2 (18) 7 (28)
RANO (MRI, clinical, steroids) (n, 
%)
  PD 8 (22) n.a. 3 (27) 5 (20)
  SD 7 (19) 2 (18) 5 (20)
  PR 10 (27) 4 (36) 6 (24)
  CR 2 (5) 0 2 (8)
  Data incomplete 9 (25) 2 (18) 7 (28)
iRANO (considering MRI only) 
(n, %)
  PD 0 0 0
  SD 16 (44) n.a. 6 (54) 10 (40)
  PR 10 (28) 4 (36) 6 (24)
  CR 2 (1) 0 2 (8)
  Data incomplete 8 (22) 1 (9) 7 (28)
iRANO (MRI, clinical, steroids) 
(n, %)
  PD 2 (5) n.a. 1 (9) 1 (4)
  SD 14 (39) 5 (45) 9 (36)
  PR 10 (28) 4 (36) 6 (24)
  CR 2 (5) 0 2 (8)
  Data incomplete 8 (22) 1 (9) 7 (28)
MRI response for overall brain 
at 3 months
(n=39)* (n=3)* (n=11)* (n=25)*
Local assessment (n, %)
  PD 13 (30) 1 (33) 5 (33) 7 (22)
  SD 13 (30) 2 (66) 4 (27) 7 (22)
  PR/CR 17 (39) 0 6 (40) 11 (34)
  Data incomplete 0 0 0 0
  (n=43)† (n=3)† (n=15)† (n=25)†
Continued
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All patients
Group 1 Group 2 Group 3
ICI alone
SRT without or with non- 
ICI pharmacotherapy ICI plus SRT
RECIST V.1.1 (MRI only) (n, %)
  PD 12 (31) 2 (66) 4 (36) 6 (24)
  SD 10 (26) 0 3 (27) 7 (28)
  PR 10 (26) 0 4 (36) 6 (24)
  CR 2 (5) 0 0 2 (8)
  Data incomplete 5 (13) 1 (33) 0 4 (16)
RANO (MRI, clinical, steroids) (n, 
%)
  PD 12 (31) 2 (66) 4 (36) 6 (24)
  SD 10 (26) 0 3 (27) 7 (28)
  PR 10 (26) 0 4 (36) 6 (24)
  CR 2 (5) 0 0 2 (8)
  Data incomplete 5 (13) 1 (33) 0 4 (16)
iRANO (considering MRI only) 
(n, %)
  PD 7 (18) 2 (66) 2 (18) 3 (12)
  SD 15 (38) 0 5 (45) 10 (40)
  PR 10 (26) 0 4 (36) 6 (24)
  CR 2 (5) 0 0 2 (8)
  Data incomplete 5 (13) 1 (33) 0 4 (16)
iRANO (MRI, clinical, steroids) 
(n, %)
  PD 8 (20) 2 (66) 3 (27) 3 (12)
  SD 14 (36) 0 4 (36) 10 (40)
  PR 10 (26) 0 4 (36) 6 (24)
  CR 2 (5) 0 0 2 (8)
  Data incomplete 5 (13) 1 (33) 0 4 (16)
MRI response (for SRT targets 
in groups 2 and 3) at 6 months
(n=20)* (n=8)* (n=12)*
Local assessment (n, %)
  PD 1 (4) n.a. 0 1 (8)
  SD 9 (39) 5 (45) 4 (33)
  PR/CR 10 (43) 5 (45) 5 (4)
  Data incomplete 2 (9) 1 (9) 2 (17)
  (n=23)† (n=11)† (n=12)†
RECIST 1.1 (MRI only) (n, %)
  PD 2 (10) n.a. 2 (18) 0
  SD 4 (20) 1 (12) 3 (25)
  PR 7 (35) 4 (50) 3 (25)
  CR 3 (15) 0 3 (25)
  Data incomplete 4 (20) 1 (12) 3 (25)
RANO (MRI, clinical, steroids) (n, 
%)
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All patients
Group 1 Group 2 Group 3
ICI alone
SRT without or with non- 
ICI pharmacotherapy ICI plus SRT
  SD 4 (20) 1 (12) 3 (25)
  PR 7 (35) 4 (50) 3 (25)
  CR 3 (15) 0 3 (25)
  Data incomplete 4 (20) 1 (12) 3 (25)
iRANO (considering MRI only) 
(n, %)
  PD 0 0 0
  SD 7 (35) n.a. 4 (50) 3 (25)
  PR 7 (35) 4 (50) 3 (25)
  CR 3 (15) 0 3 (25)
  Data incomplete 3 (15) 0 3 (25)
  (n=20) (n=8) (n=12)
iRANO (MRI, clinical, steroids) 
(n, %)
  PD 1 (5) n.a. 1 (12) 0
  SD 6 (30) 3 (37) 3 (25)
  PR 7 (35) 4 (50) 3 (25)
  CR 3 (15) 0 3 (25)
  Data incomplete 3 (15) 0 3 (25)
  (n=20) (n=8) (n=12)
MRI response for overall brain 
at 6 months
(n=21)* (n=1)* (n=8)* (n=12)*
Local assessment (n, %)
  PD 4 (17) 1 (100) 2 (18) 1 (0.5)
  SD 10 (42) 0 5 (45) 5 (42)
  PR/CR 10 (42) 0 4 (36) 6 (50)
  Data incomplete 0 0 0 0
  (n=24)† (n=1)† (n=11)† (n=12)†
RECIST V.1.1 (MRI only) (n, %)
  PD 3 (14) 0 3 (37) 0
  SD 7 (33) 0 2 (25) 5 (42)
  PR 6 (28) 0 3 (37) 3 (25)
  CR 3 (14) 0 0 3 (25)
  Data incomplete 2 (9) 1 (100) 0 1 (8)
RANO (MRI, clinical, steroids) (n, 
%)
  PD 3 (14) 0 3 (37) 0
  SD 7 (33) 0 2 (25) 5 (42)
  PR 6 (28) 0 3 (37) 3 (25)
  CR 3 (14) 0 0 3 (25)
  Data incomplete 2 (9) 1 (100) 0 1 (8)
iRANO (considering MRI only) 
(n, %)
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All patients
Group 1 Group 2 Group 3
ICI alone
SRT without or with non- 
ICI pharmacotherapy ICI plus SRT
  SD 8 (38) 0 3 (37) 5 (42)
  PR 6 (28) 0 3 (37) 3 (25)
  CR 3 (14) 0 0 3 (25)
  Data incomplete 2 (9) 1 (100) 0 1 (8)
iRANO (MRI, clinical, steroids) 
(n, %)
  PD 2 (9) 0 2 (25) 0
  SD 8 (38) 0 3 (37) 5 (42)
  PR 6 (28) 0 3 (37) 3 (25)
  CR 3 (14) 0 0 3 (25)
  Data incomplete 2 (9) 1 (100) 0 1 (8)
*Number of MRI scans available for central review.
†Number of patients evaluated locally.
CR, complete response; ICI, immune checkpoint inhibition; iRANO, immunotherapy response assessment in neuro- oncology; n, number of 
patients; PD, progressive disease; PR, partial response; RANO, response assessment in neuro- oncology; RECIST, response evaluation criteria 
in solid tumours; SD, stable disease; SRT, stereotactic radiotherapy.
Table 3 Continued
patients across criteria used. CRs were only observed in 
group 3. One patient had clinical deterioration without 
MRI progression at the first scan which accounts for the 
higher rate of PD as best response with RANO versus 
RECIST. The rates of CR and PR as best response in irra-
diated patients for overall whole brain were identical to 
those for the stereotactic radiosurgery targets, suggesting 
that patients who respond to SRT locally rarely show 
distant progression at this time point. Formally, when MRI 
iRANO criteria were used, 7 patients (11%) showed PD as 
the best response versus 11 patients (18%) had PD as the 
best response using RECIST or RANO criteria (table 4).
Pseudoprogression and radionecrosis
We noted seven instances of pseudoprogression, three 
patients in group 2 and four patients in group 3, all within 
6 months. It appeared to be more common in patients 
with cystic lesions. No patient diagnosed with pseudo-
progression achieved a CR without further intervention 
subsequently. Radionecrosis occurred in seven patients, 
too, two in group 2 and five in group 3, again all within 
6 months. It appeared to be more common in patients 
with a BM diameter above 30 mm (online supplementary 
table S5). The seven patients with pseudoprogression 
were different from the seven patients with radionecrosis.
We also compared the effects of single fraction (n=27) 
versus multiple fraction (n=25) SRT. Pseudoprogres-
sion was more common after single fraction SRT than 
after multiple fraction SRT: five of seven patients with 
pseudoprogression had received single fraction SRT, 
three SRT alone and two SRT plus ICI. In contrast, only 
two of the seven patients with pseudoprogression had 
received multiple fraction SRT, both in combination 
with ICI. Radionecrosis was also more common after 
single fraction SRT than after multiple fraction SRT: five 
of seven patients with radionecrosis had received single 
fraction SRT, two SRT alone and three SRT plus ICI. In 
contrast, only two of the seven patients with radionecrosis 
had received multiple fraction SRT, both in combination 
with ICI.
abscopal effects
No evidence for abscopal effects of SRT were seen. Only 
two group 2 patients had more BM than those treated by 
SRT, three BM but only two treated or six BM but only 
three treated; both patients had global brain PD at 3 
months whereas the treated SRT lesions were stable or 
progressive, too (figure 3). Further, we compared the 10 
patients treated by ICI alone (group 1) with 5 patients 
of group 3 who had more BM lesions than SRT targets. 
There were no responses in group 1. Similarly, none 
of the five patients who did not have SRT to all lesions 
showed a response of a non- irradiated lesion, but these 
patients may present a priori a negative selection because 
they also showed poor control of their irradiated lesions 
(table 5). Finally, one might argue that the rate of new 
BM after initial treatment might provide weak evidence 
for abscopal effects: in that regard, we noted 6 new BM 
(60%) after a median of 2 months in group 1, 11 new BM 
(55%) after a median of 3.9 months in group 2, and 12 
new BM including one case of LM (37.5%) after a median 
of 3.7 months in group 3.
dIsCussIon
Clinical decision making and response assessment in 
patients with BM from melanoma remain challenging, 
notably if systemic therapy and SRT are combined. Several 
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Best MRI response for SRT targets 
in groups 2 and 3
(n=40)* (n=15)* (n=25)*
Local assessment (n=52)†
  PD 10 (19) n.a. 4 (20) 6 (19)
  SD 20 (38) 7 (35) 13 (41)
  PR/CR 18 (35) 8 (40) 10 (31)
  Data unavailable 4 (8) 1 (5) 3 (9)
RECIST V.1.1 (MRI only) (n=40)
  PD 7 (17) n.a. 3 (20) 4 (16)
  SD 8 (20) 2 (13) 6 (24)
  PR 7 (17) 4 (27) 3 (12)
  CR 6 (15) 0 6 (24)
  Data unavailable 12 (30) 6 (40) 6 (24)
RANO (MRI, clinical, steroids) (n=40)
  PD 9 (2) n.a. 4 (27) 5 (20)
  SD 6 (15) 2 (13) 4 (16)
  PR 7 (16) 4 (27) 3 (12)
  CR 6 (15) 0 6 (24)
  Data unavailable 12 (30) 5 (33) 7 (28)
iRANO (considering MRI only) (n=40)
  PD 0 n.a. 0 0
  SD 15 (37) 6 (40) 9 (36)
  PR 8 (20) 5 (33) 3 (12)
  CR 6 (15) 0 6 (24)
  Data unavailable 11 (27) 4 (27) 7 (28)
iRANO (MRI, clinical, steroids) (n=40)
  PD 3 (7) n.a. 2 (10) 1 (4)
  SD 14 (35) 5 (33) 8 (32)
  PR 7 (17) 4 (27) 3 (12)
  CR 6 (15) 0 6 (24)
  Data unavailable 11 (27) 4 (27) 7 (28)
Best MRI response for overall brain (n=43) (n=3) (n=15) (n=25)
Local assessment (n=62)†
  PD 24 (39) 6 (60) 8 (40) 10 (31)
  SD 15 (24) 2 (20) 4 (20) 9 (28)
  PR/CR 19 (31) 0 7 (35) 12 (37)
  Data unavailable 4 (6) 2 (20) 1 (5) 1 (3)
RECIST V.1.1 (MRI only) (n=43)
  PD 13 (30) 2 (66) 5 (33) 6 (24)
  SD 9 (21) 0 3 (20) 6 (24)
  PR 7 (16) 0 4 (27) 3 (12)
  CR 6 (14) 0 0 6 (24)
  Data incomplete 8 (19) 1 (33) 3 (20) 4 (16)
Continued
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RANO (MRI, clinical, steroids) (n=43)
  PD 13 (30) 2 (67) 5 (33) 6 (24)
  SD 9 (1) 0 3 (20) 6 (24)
  PR 7 (16) 0 4 (27) 3 (12)
  CR 6 (14) 0 0 (0) 6 (24)
  Data unavailable 8 (19) 1 (33) 3 (20) 4 (16)
iRANO (considering MRI only) (n=43)
  PD 8 (13) 2 (67) 3 (20) 3 (12)
  SD 13 (21) 0 4 (27) 9 (36)
  PR 8 (13) 0 5 (33) 3 (12)
  CR 6 (10) 0 0 6 (24)
  Data unavailable 8 (19) 1 (33) 3 (20) 4 (16)
iRANO (MRI, clinical, steroids) (n=43)
  PD 8 (13) 2 (67) 3 (20) 3 (12)
  SD 13 (30) 0 4 (27) 9 (36)
  PR 8 (19) 0 5 (33) 3 (12)
  CR 6 (14) 0 0 6 (24)
  Data unavailable 8 (19) 1 (33) 3 (20) 4 (16)
Pseudoprogression and 
radionecrosis
(n=43) (n=0) (n=15) (n=25)
Pseudoprogression (n, %) 7 (16) 0 3 (20) 4 (16)
Detected first on MRI at
  3 months 4 (57) 0 3 (100) 1 (25)
  6 months 3 (43) 0 0 3 (75)
  9 months 0 0 0 0
  12 months 0 0 0 0
Radionecrosis (n, %) 7 (16) 0 2 (13) 5 (20)
Detected first on MRI at
  3 months 6 (86) 0 1 (50) 5 (100)
  6 months 1 (14) 0 1 (50) 0 (0)
  9 months 0 0 0 (0) 0 (0)
  12 months 0 0 0 (0) 0 (0)
*Number of MRI scans available for central review.
†Number of patients evaluated locally.
CR, complete response; ICI, immune checkpoint inhibition; iRANO, immunotherapy response assessment in neuro- oncology; n, number of 
patients; PD, progressive disease; PR, partial response; RANO, Response assessment in neuro- oncology; RECIST, Response Evaluation 
Criteria in Solid Tumours; SD, stable disease; SRT, stereotactic radiotherapy
Table 4 Continued
series of patients with melanoma and lung cancer with 
BM treated with SRT or ICI or their combination have 
recently been reported,1 4–6 12–18 but the best timing and 
sequencing of these treatments remains controversial. 
Here we retrospectively applied different sets of response 
criteria to a cohort of 62 such patients from two centres 
to investigate current patterns of decision making and 
the potential usefulness of RECIST versus RANO versus 
iRANO criteria in this setting. Outcome was inferior in 
patients treated with ICI alone than in patients receiving 
SRT alone or in combination with systemic therapy, and 
CRs were only observed in group 3 patients that had SRT 
combined with ICI (figure 1, tables 2 and 3). The higher 
rate of LM in operated patients supports the development 
of surgical strategies seeking to avoid this complication.
Assessment of SRT- treated targets revealed low CR and 
similar overall response rates independent of criteria 
used. Using RANO instead of RECIST may increase the 
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Figure 3 Absence of abscopal effects (case presentation). 
Stable disease of stereotactic radiotherapy (SRT) treated 
lesion (bottom panel), but detection of new lesions at first 
follow- up (arrows).
Table 5 Exploration of the abscopal effect: best brain 







ICI plus SRT: patients 
with more BM than SRT 
targets (n=5)
Local assessment (n, %)
  PD 3 (20) 1 (10) 2 (40)
  SD 3 (20) 2 (20) 1 (20)
  PR/CR 0 0 0
  Data incomplete 9 (60) 7 (70) 2 (40)
  (9 PD prior to 
3 months)
(7 PD prior to 
3 months)
(2 PD prior to 3 months)
RECIST V.1.1 (MRI only)
  PD 5 (23) 2 (20) 3 (60)
  SD 0 0 0
  PR 0 0 0
  CR 0 0 0
  Data incomplete 10 (67) 8 (80) 2 (40)
  (9 PD prior to 
3 months)
(7 PD prior to 
3 months)
(2 PD prior to 3 months)
RANO (MRI, clinical, steroids)
  PD 5 (23) 2 (20) 3 (60)
  SD 0 0 0
  PR 0 0 0
  CR 0 0 0
  Data incomplete 10 (67) 8 (80) 2 (40)
  (9 PD prior to 
3 months)
(7 PD prior to 
3 months)
(2 PD prior to 3 months)
iRANO (considering MRI only)
  PD 3 (20) 2 (20) 1 (20)
  SD 2 (13) 0 2 (40)
  PR 0 0 0
  CR 0 0 0
  Data incomplete 10 (67) 8 (80) 2 (40)
  (9 PD prior to 
3 months)
(7 PD prior to 
3 months)
(2 PD prior to 3 months)
iRANO (MRI, clinical, steroids)
  PD 3 (20) 2 (20) 1 (20)
  SD 2 (13) 0 2 (40)
  PR 0 0 0
  CR 0 0 0
  Data incomplete 10 (67) 8 (80) 2 (40)
  (9 PD prior to 
3 months)
(7 PD prior to 
3 months)
(2 PD prior to 3 months)
BM, brain metastasis; CR, complete response; ICI, immune checkpoint inhibition; 
iRANO, immunotherapy response assessment in neuro- oncology; n, number of 
patients; PD, progressive disease; PR, partial response; RANO, response assessment 
in neuro- oncology; RECIST, response evaluation criteria in solid tumours; SD, stable 
disease; SRT, stereotactic radiotherapy.
rate of early PD because clinical deterioration was occa-
sionally noted in patients with MRI findings that did not 
yet qualify for PD (data not shown). Application of iRANO 
criteria lowers the early PD rate because of the require-
ment for a confirmatory scan in patients with suspected 
MRI progression who are clinically stable (table 3).
The absence of pseudoprogression in patients treated 
with ICI alone suggests that an increase in lesion size 
in such patients should commonly trigger a change 
in management, for example, probably SRT in most 
instances. The numerically lower rate of pseudoprogres-
sion in group 3 versus group 2 also does not support 
concerns regarding our capability to determine response 
in ICI- treated patients. Not surprisingly, the rate of pseu-
doprogression and radionecrosis were higher after single 
fraction compared with multiple fraction SRT.
Abscopal effects remain to be discussed in the context 
of BM treated with SRT, but clinical evidence is virtually 
absent. We identified only two patients treated with SRT 
alone who did not have SRT to all lesions. These are the 
ideal patients to explore abscopal effects, and there were 
none. Supportive evidence for abscopal effects could also 
be derived if patients treated with SRT for some lesions 
combined with ICI showed a better overall brain response 
than patients treated with ICI alone. However, we saw no 
response of non- irradiated lesions in any of five such 
patients, providing no evidence for abscopal effects of 
SRT when combined with ICI either.
This report has major limitations, including its retro-
spective nature associated with lack of standardised 
delivery of SRT (single fraction in Lille vs multiple frac-
tions in Zurich), lack of standardised follow- up, the small 
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sample size per group and the uncontrolled assignment 
of treatment. Its strength may be the identification of 
shortcomings in the currently applied response criteria 
which may guide the continuous efforts of improving 
and standardise how we monitor patients with BM by 
clinical and neuroimaging assessment. The survival data 
observed here may support recent concerns that the 
omission of SRT from first- line treatment may compro-
mise outcome.19
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